MARKSANS PHARMA LTD. - 524404 - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We enclose herewith Certificate issued by Sanjay Dholakia, Company Secretaries for the year ended 31st March, 2022 as required under Regulation 40(9) & 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2022 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company. MARKSANS PHARMA LTD. - 524404 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith Compliance Certificate pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended 31st March, 2022 MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of the Company''s code of conduct to regulate, monitor and report trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of Marksans Pharma Limited ('the Company') for the designated persons of the Company will remain closed from Friday, 1st April, 2022 till 48 hours after the declaration of audited financial results for the quarter and financial year ended 31st March, 2022. The date of declaration of audited financial results will be intimated separately in due course of time. Designated Persons of the Company and/or their immediate relatives shall not trade in the shares of the Company during the aforesaid period of closure of trading window. MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for loss of share certificate as per Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited announces UK MHRA approval for Bells Healthcare All in One Oral Solution.
Buy Marksans Pharma; target of Rs 86: Arihant Capital
Arihant Capital is bullish on Marksans Pharma has recommended buy rating on the stock with a target price of Rs 86 in its research report dated February 16, 2022.
Earnings Call for Q3FY22 of Marksans Pharma
Conference Call with Marksans Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.